Skip to main content
The Evidence Base Post

MHRA outlines real-world data priorities for women’s health

  • Katie McCool
Female doctor wearing a stethoscope smiles while speaking with a woman during a medical consultation in a clinic.

The UK’s Medicines and Healthcare products Regulatory Agency has published a new program setting out its priorities for addressing evidence gaps in women’s health from 2026 to 2030. The initiative aims to strengthen the use of real-world data, improve women’s representation in clinical research, and better understand differences in the safety and effectiveness of medicines and medical devices. It also outlines measures to support innovation and inform treatment decisions.


The Baseline

  • The MHRA has published its Women’s Health Program 2026–2030, outlining priorities to address evidence gaps and improve women’s health throughout their lives.
  • Priorities include expanding real-world data use, improving representation in clinical research and identifying sex-based differences in treatment safety and effectiveness.
  • The program also addresses evidence generation during pregnancy and breastfeeding, regulatory support for FemTech, and improved communication of sex-specific findings.

Published on November 16, 2026, the MHRA Women’s Health Programme 2026–2030 aims to improve women’s health at every stage of life, addressing conditions specific to women, those that disproportionately affect them and those that affect women differently. The program follows an MHRA analysis of 4,616 UK clinical trial applications submitted between 2019 and 2023, which found that pregnant women were represented in 1.1% of trials and breastfeeding women in 0.6%. Only 33% of trials approved during this period included women of childbearing potential.

Expanding the use of real-world data (RWD) is a central priority, particularly for identifying sex-based differences in the safety and effectiveness of medicines and medical devices. The MHRA plans to use analyses stratified by sex throughout the product lifecycle, drawing on multiple data sources, including patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs). It also intends to identify products, therapeutic areas, and populations where evidence is limited, working with NHS organizations, academic researchers, and data custodians to address these gaps.

The program also explores the potential of AI, advanced modeling, and synthetic data to investigate outcomes where evidence is limited. The MHRA acknowledges the potential for these approaches to reproduce existing biases and emphasizes the need for appropriate validation and governance.

To strengthen regulatory decision-making, the agency intends to establish consistent processes for submitting and evaluating sex-disaggregated data before and after authorization. Planned activities include developing guidance, improving analytical capabilities, and incorporating relevant findings into product information to support treatment decisions.

Lawrence Tallon, MHRA Chief Executive, said:

“Better evidence can help us understand where important differences exist, support researchers and innovators and create opportunities for healthcare that is better tailored to women’s needs.” 

Beyond its proposed changes to data analysis and regulatory assessment, the program identifies three additional priorities:

  1. Innovation: Supporting the development and regulation of FemTech and other healthcare products addressing unmet clinical needs through regulatory guidance and existing pathways.
  2. Pregnancy and breastfeeding: Piloting approaches to evidence generation using RWD and totality-of-evidence frameworks, strengthening post-authorization monitoring and improving information on treatment risks and benefits to support informed treatment decisions for pregnant and breastfeeding women.
  3. Communication and collaboration: Developing guidance on communicating sex-specific outcomes and strengthening partnerships across the healthcare system and with international regulators.

The program also complements existing efforts to improve representation in clinical research, including joint guidance from the MHRA and Health Research Authority on developing Inclusion and Diversity Plans.

Naho Yamazaki, Deputy Director of Policy and Partnerships at the Health Research Authority, reinforced the importance of including under-represented populations in clinical trials:

“Ensuring that people who are under-represented in research are considered and included in clinical trials is essential if research is to generate evidence that is relevant to the populations who will ultimately use new medicines and treatments.”

The announcement has also attracted positive responses from stakeholders on the MHRA’s LinkedIn post, with comments drawing attention to the importance of inclusive study design, early patient involvement and addressing evidence gaps beyond clinical trials.

Among those welcoming the initiative, Grammati Sarri (Cytel) praised its combination of scientific rigor and statistical innovation, while questioning whether health technology assessment bodies would follow a similar approach:

“By pairing strict scientific standards with statistical innovation, the MHRA isn't just catching up on women's health, it is setting a new global benchmark for how regulators can actively eliminate sex-based health inequalities. Hopefully, it is time for HTA bodies to catch up?”

Developed with input from patients and healthcare stakeholders, the program forms part of the MHRA’s wider strategy to 2030 and aligns with UK initiatives to address health inequalities. The program was officially launched at the inaugural DIA–MHRA Global Summit, held in London on November 16–17, 2026 as part of London Life Sciences Week. Implementation will involve continued patient engagement and evaluation of the program’s activities and outcomes.

Register for free today to become a member of The Evidence Base and receive the latest news straight to your inbox.